Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Plamotamab · 1 trial · 1 indication
Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Plamotamab administered SC |
| Name | Type | Description |
|---|---|---|
| Plamotamab | BIOLOGICAL | Biological |
Inclusion Criteria: Adult participants with moderately to severely active RA. * Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening * Inadequate respon...
Top 20 of 31 competitors
Plamotamab is an investigational monoclonal antibody being studied for the treatment of Rheumatoid Arthritis. It is currently in Phase 1 clinical development, with an ongoing open-label trial evaluating its safety in participants with this condition.
Plamotamab targets CD20, a protein found on the surface of B cells. By binding to CD20, the antibody is designed to deplete B cells, which are implicated in the autoimmune response driving Rheumatoid Arthritis.
Plamotamab is being developed by Xencor, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol XNCR.
Plamotamab is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1b trial is currently recruiting participants to evaluate its safety in Rheumatoid Arthritis.
Plamotamab is being studied in a single Phase 1b open-label trial with the identifier NCT07230353. This trial is recruiting 68 participants with Rheumatoid Arthritis across sites in Georgia, Moldova, and New Zealand, and is not yet completed.